Image: Associated Press
Astellas snags a gene therapy upstart with $3B buyout bid — inspiring forecasts of more M&A ahead
Astellas has moved in to buy a biotech upstart with a new approach to developing a gene therapy for Duchenne muscular dystrophy.
The Japanese pharma …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
